Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer

The best available evidence suggests that pregnancy after breast cancer does not increase a woman's risk of developing a recurrence from her breast cancer. In particular, the most recent data suggest that this is the case also in women with a hormone receptor-positive breast cancer. There is also no indication of increased risk for delivery complications or for the newborn. The aim of the study is to investigate if temporary interruption of endocrine therapy, with the goal to permit pregnancy, is associated with a higher risk of breast cancer recurrence.The study aims also to evaluate different specific indicators related to fertility, pregnancy and breast cancer biology in young women. A psycho-oncological companion study on fertility concerns, psychological well-being and decisional conflicts will be conducted in interested Centers.

Research Base: International Breast Cancer Study Group
NCT ID: NCT02308085
NCI Protocol Number: A221405
Status: Recruiting

For more information see ClinicalTrials.gov

Interventions

Endocrine therapy interruption

Condition

Early Breast Cancer

Trial Type

Supportive Care/Symptom Management/PROs

See a list of participating sites on ClinicalTrials.gov


˄
BACK TO
TOP